Benzamide ligands for the thyroid receptor
US6395784B1 · kind B1 · utility
Assignee
Inventor
Key dates
| Filing date | May 31, 2001 |
| Grant date | May 28, 2002 |
| Priority date | — |
| Expiry date | May 31, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2601/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
New thyroid receptor ligands are provided which have the general formula in which:X is —O—, —S—, —CH2—, —CO—, or —NH—;R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons;R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 6 carbons, at least one of R2 and R3 being other than hydrogen;R4 is methyl, ethyl, n-propyl or trifluoromethyl;R5 is hydrogen or lower alkyl;R6 is carboxylic acid, or esters or prodrugs;R7 is hydrogen or an alkanoyl or an aroyl.In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T3 regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.